“Methods: We conducted a national, matched, test-negative, case–control study in Qatar from December 23, 2021, through February 21, 2022, to evaluate the effectiveness of vaccination with BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic omicron infection and against severe, critical, or fatal coronavirus disease 2019 (Covid-19).
Conclusions: No discernible differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity.”
© 2023 Massachusetts Medical Society. All rights reserved. NEJM Group content is protected by copyright. While many NEJM Group content items such as articles, figures, tables, videos, and podcasts are free online, NEJM Group content is for personal, non-commercial use in accordance with copyright law. Reuse of Content Within a Thesis or Dissertation Content (full-text or portions thereof) may be used in print and electronic versions of a dissertation or thesis without formal permission from the Massachusetts Medical Society (MMS), Publisher of the New England Journal of Medicine. The following credit line must be printed along with the copyrighted material: Reproduced with permission from (scientific reference citation), Copyright Massachusetts Medical Society. Source: https://www.nejm.org/about-nejm/permissions